# Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension

> **NCT07697235** · NA · NOT_YET_RECRUITING · sponsor: **University Hospital, Strasbourg, France** · enrollment: 22 (estimated)

## Conditions studied

- PAH

## Interventions

- **DIETARY_SUPPLEMENT:** OMega 3

## Key facts

- **NCT ID:** NCT07697235
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-03
- **Final completion:** 2030-03
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07697235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07697235, "Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07697235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*